Sanofi buys US haemophilia treatment firm for $11.6 bn (Update)
French pharmaceutical firm Sanofi said Monday it had reached an agreement to purchase US biotech company Bioverativ, which specialises in treatments for haemophilia and rare blood disorders, for $11.6 billion.
Jan 22, 2018
0
5